Cancel
Clene Nanomedicine
See Linkedin
Clene Nanomedicine Employees
13 people indexed:
-
49y3@zzbz7.69q Sign up to see email
-
852fqy@x3khb.f67 Sign up to see email
-
5xp0v5uq@dfr72.02h Sign up to see email
-
j@7590v.558 Sign up to see email
-
iu9i2@uw0h4.gh8 Sign up to see email
-
hqs4hg@8yxg3.69r Sign up to see email
-
41sgw@7y364.dwy Sign up to see email
-
u633@2ts48.iuj Sign up to see email
-
9f30@kuk2b.g37 Sign up to see email
-
pt31k23@k03sd.tfx Sign up to see email
-
8fx1vj@9sufj.i9x Sign up to see email
-
g88@8d5w6.jjq Sign up to see email
-
gh5pp5@t5fvz.pzq Sign up to see email
Clene Nanomedicine Company Information
Clene Nanomedicine, headquartered in Salt Lake City, Utah, specializes in the development of innovative nanotherapeutics aimed at addressing cellular energy impairments found in neurodegenerative diseases such as ALS, MS, and Parkinson’s Disease. The company is advancing a pipeline of clean-surfaced, catalytically-active nanocrystals designed for therapeutic use. Its lead drug candidate, CNM-Au8, is a suspension of gold nanocrystals intended as a disease-modifying treatment. Clene Nanomedicine conducts multiple clinical trials for CNM-Au8, which are registered on clinicaltrials.gov. Additionally, the company operates a manufacturing and R&D facility in North East, Maryland, and offers an Expanded Access Program (EAP) for investigational medicines, providing treatments under specific eligibility criteria to patients who do not qualify for clinical trials.
Report inaccurate information
Report inaccurate information
